updated 8/3/2004 3:22:04 PM ET 2004-08-03T19:22:04

A substance long used to make dissolvable stitches now can help plump up faces left sunken and gaunt by the AIDS virus, the Food and Drug Administration ruled Tuesday.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

The FDA’s approval of Sculptra, an injectable filler, marks the first treatment specifically for the loss of facial fat common among HIV patients.

Called lipoatrophy, in severe cases patients are left with sunken-looking cheeks and eyes that can dramatically affect quality of life. No one is sure what causes the fat loss, although it seems to be associated with anti-HIV therapies. Estimates are that 20 percent to 50 percent of HIV patients experience some degree of lipoatrophy.

Sculptra is a form of a polymer used for decades to create dissolvable stitches. In its injectable form, it has been used as a wrinkle filler in Europe since 1999.

In approving U.S. sales, FDA cited research showing Sculptra improved facial shape and appearance when injected into sunken areas of HIV patients’ faces. While some patients’ effects may last two years, the substance can break down so repeat treatments may be necessary, FDA cautioned.

Side effects include skin nodules, redness, swelling and bruising at the injection site.

Studies to date have primarily included white men. As a condition of approval, FDA told maker Dermik Laboratories to track 100 patients for five years — including at least 30 women and 30 patients with dark skin — to monitor long-term effects.

FDA said Sculptra should be used only by health-care providers familiar with Dermik’s training materials, and warned that the drug has not been approved for wider cosmetic use such as wrinkle-filling.

Dermik, the dermatology division of drug-giant Aventis, refused to reveal the drug’s planned price.

© 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments